National survey of Canadian Retina Society members on guidelines for ophthalmic care during the COVID-19 crisis: Canadian Retina Research Network (CR2N) COVID-19 Steering Committee analysis

Varun Chaudhary, Daniel Rosenberg, Joshua Barbosa, Cynthia Qian, Alan Berger, James Whelan, Amin Kherani, Arif Samad, Jason Noble

Research output: Contribution to journalLetterpeer-review

3 Citations (Scopus)
Original languageEnglish
Pages (from-to)452-454
Number of pages3
JournalCanadian Journal of Ophthalmology
Volume55
Issue number5
DOIs
Publication statusPublished - Oct 2020

Bibliographical note

Funding Information:
Dr. Varun Chaudhary has investigator-sponsored research grants and participates in clinical trials funded by Novartis, Bayer, and Allergan; Dr. Chaudhary has also served on the advisory board and is consultant for Novartis and Bayer. Dr. Cynthia Qian has served as consultant for Novartis, Bayer, Allergan, and Bausch and Lomb. Dr. Alan Berger serves as consultant and receives honoraria from Novartis, Bayer, Allergan, and Roche. Dr. James Whelan has received honoraria from Alcon, Novartis, and Bayer, and has investigator-sponsored research grants from Novartis. Dr. Amin Kherani participates in clinical trials funded by Novartis, Bayer, Allergan, Alcon, and Bausch and Lomb. Dr. Arif Samad participates in clinical trials funded by, and is consultant with, Novartis and Bayer. Dr. Jason Noble serves on the advisory board of Novartis and Bayer, and is a speaker for Novartis. None of these have any bearing on the current study. The remaining authors have no financial disclosures to declare. This research did not receive any funding or grants from agencies in the public, commercial, or not-for-profit sectors.

Funding Information:
?, Dr. Varun Chaudhary has investigator-sponsored research grants and participates in clinical trials funded by Novartis, Bayer, and Allergan; Dr. Chaudhary has also served on the advisory board and is consultant for Novartis and Bayer. Dr. Cynthia Qian has served as consultant for Novartis, Bayer, Allergan, and Bausch and Lomb. Dr. Alan Berger serves as consultant and receives honoraria from Novartis, Bayer, Allergan, and Roche. Dr. James Whelan has received honoraria from Alcon, Novartis, and Bayer, and has investigator-sponsored research grants from Novartis. Dr. Amin Kherani participates in clinical trials funded by Novartis, Bayer, Allergan, Alcon, and Bausch and Lomb. Dr. Arif Samad participates in clinical trials funded by, and is consultant with, Novartis and Bayer. Dr. Jason Noble serves on the advisory board of Novartis and Bayer, and is a speaker for Novartis. None of these have any bearing on the current study. The remaining authors have no financial disclosures to declare. This research did not receive any funding or grants from agencies in the public, commercial, or not-for-profit sectors.

ASJC Scopus Subject Areas

  • Ophthalmology

Cite this